secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001746473-25-000105
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve charter amendment to limit officer liability; elect three Class II directors
--------------------------------------------------------------------------------

- Amendment limiting officer liability approved with 35.2M For, 3.8M Against, 881.7K Abstain; filed June 9, 2025.
- Class II directors elected: John Curnutte (34.5M For), Katharine Knobil (26.7M For), Thomas McCourt (31.6M For).
- Advisory say-on-pay passed with 30.0M For, 8.9M Against, 910.9K Abstain.
- Ratification of Deloitte as auditor for FY2025 approved with 50.8M For, 506K Against, 931K Abstain.
- Broker non-votes totaled 12.35M shares on all proposals except auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000105/0001746473-25-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000105/plrx-20250605.htm
  HTML page:      https://secwatch.observer/filing/0001746473-25-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer